Dilini Christina Ranasinghe: Paediatric TPE Is Not Simply Adult TPE in a Smaller Patient
Dilini Christina Ranasinghe, Registrar in Transfusion Medicine at National Blood Centre, shared a post on LinkedIn:
“Paediatric TPE is not simply ‘adult TPE in a smaller patient’
Therapeutic plasma exchange (TPE) in children requires a different level of procedural planning and vigilance.
Key paediatric considerations include:
Extracorporeal volume and blood priming
In children, the circuit volume may represent a significant proportion of total blood volume. Initiating TPE with a saline-primed circuit can lead to haemodilution and hypotension. Blood priming with compatible red cells helps maintain haemodynamic stability and improves tolerance.
Vascular access and line position
Central lines may be malpositioned into unintended vessels or advanced too far due to smaller anatomy. This can lead to poor flow, ineffective exchange, or arrhythmias if the tip irritates the atrial wall — making confirmation of position with imaging essential before starting TPE.
Continuous rather than intermittent exchange
Children tolerate rapid intravascular shifts poorly. A controlled, continuous exchange allows gradual removal and replacement, improving haemodynamic stability.
Continuous monitoring and vigilance
With limited physiological reserve, deterioration can be rapid.
Close monitoring of haemodynamics, electrolytes (especially calcium), access pressures, and clinical status is essential.
Early recognition of subtle changes is key to preventing significant complications.
Team coordination
Safe paediatric TPE requires coordination between paediatric specialties, transfusion medicine, ICU teams when required, and microbiology, across all staff categories — ensuring safe delivery in different care settings.
In paediatric TPE, safety lies in anticipating physiological changes and responding before instability develops.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
-
Aug 31, 2026, 14:23Accelerating CAR-T Access Through Policy and System Reform – American Society of Hematology
-
Aug 31, 2026, 14:21Shirya Rashid: Does Bempedoic Acid Influence Venous Thromboembolism Risk?
-
Aug 31, 2026, 14:14Jason Andrade: SINGLE-AF Trial Validates Early Anticoagulation in AF
-
Aug 31, 2026, 14:12Leonardo Roever: Diagnosis and Management of Natural Anticoagulant Deficiencies
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery